NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview

NGM Biopharmaceuticals

23/02/2024 11:56

* NGM Biopharmaceuticals Inc  NGM.OQ   NGM.O  is expected
to show
a fall in quarterly revenue when it reports  results on February
26 (estimated) for the period ending December 31 2023
    * The South San Francisco California-based  company is
expected to
report a 96.9% decrease in revenue to $558.2 thousand from
$18.18 million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for NGM Biopharmaceuticals
Inc is
for a loss of 39 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for NGM
Biopharmaceuticals Inc is $4.00​, above​ its last closing price
of $1.91. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.46       -0.42      -0.35     Beat    17.5
 Jun. 30 2023  -0.50       -0.50      -0.46     Beat    7.6
 Mar. 31 2023  -0.53       -0.52      -0.58     Missed  -12.2​
 Dec. 31 2022  -0.52       -0.51      -0.45     Beat    12.6
 ​​Sep.        -0.60       -0.59      -0.59     Met     0.3
 30 2022                                                
 Jun. 30 2022  -0.56       -0.55      -0.59     Missed  -7.3​
 Mar. 31 2022  -0.41       -0.46      -0.42     Beat    8.3
 Dec. 31 2021  -0.35       -0.36      -0.35     Beat    2.8
 This summary was machine generated February 23 at 11:55 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)